Volume 26, Issue 2, Pages (February 2018)

Slides:



Advertisements
Similar presentations
Volume 12, Issue 5, Pages (November 2005)
Advertisements

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Volume 10, Issue 2, Pages (August 2004)
Molecular Therapy - Oncolytics
Volume 25, Issue 10, Pages (October 2017)
CD271 on Melanoma Cell Is an IFN-γ-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens  Junpei Furuta, Takashi Inozume,
Volume 20, Issue 3, Pages (March 2012)
Molecular Therapy - Oncolytics
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Volume 15, Issue 2, Pages (February 2007)
by Norman Nausch, Ioanna E
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.
by Takahiro Kamiya, Desmond Wong, Yi Tian Png, and Dario Campana
Volume 40, Issue 2, Pages (February 2014)
Mycophenolic Acid Inhibits Natural Killer Cell Proliferation and Cytotoxic Function: A Possible Disadvantage of Including Mycophenolate Mofetil in the.
Volume 25, Issue 12, Pages (December 2017)
Volume 134, Issue 1, Pages (January 2008)
Volume 24, Issue 8, Pages (August 2016)
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Volume 25, Issue 3, Pages (March 2017)
Volume 10, Issue 5, Pages (November 2004)
Volume 28, Issue 4, Pages (October 2015)
Volume 25, Issue 5, Pages (May 2017)
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Volume 13, Issue 1, Pages (January 2006)
Volume 26, Issue 4, Pages (April 2018)
Volume 26, Issue 2, Pages (February 2018)
Molecular Therapy - Nucleic Acids
Volume 17, Issue 8, Pages (August 2009)
Volume 23, Issue 4, Pages (April 2015)
Volume 24, Issue 9, Pages (September 2016)
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 4, Pages (April 2018)
Volume 23, Issue 10, Pages (October 2015)
Molecular Therapy - Oncolytics
Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”  Andreas A Hombach, Gunter.
Volume 7, Issue 1, Pages (January 2003)
Volume 24, Issue 9, Pages (September 2016)
Volume 25, Issue 9, Pages (September 2017)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Volume 25, Issue 11, Pages (November 2017)
Volume 8, Issue 5, Pages (November 2010)
Volume 16, Issue 2, Pages (July 2016)
Volume 12, Issue 5, Pages (November 2005)
Volume 23, Issue 1, Pages (January 2015)
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 23, Issue 2, Pages (February 2015)
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 1, Pages (January 2017)
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Volume 24, Issue 1, Pages (January 2016)
Volume 26, Issue 1, Pages (January 2018)
Volume 17, Issue 5, Pages (May 2009)
Volume 24, Issue 2, Pages (February 2016)
Volume 25, Issue 10, Pages (October 2017)
Volume 10, Issue 6, Pages (December 2004)
Volume 8, Issue 2, Pages (August 2003)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
MRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma  Yuhua Wang, Lu Zhang, Zhenghong.
Molecular Therapy - Oncolytics
Volume 21, Issue 4, Pages (April 2013)
Volume 25, Issue 9, Pages (September 2017)
Volume 27, Issue 8, Pages (August 2019)
Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation  Venkateswara.
Volume 25, Issue 4, Pages (April 2017)
Volume 25, Issue 4, Pages (October 2006)
Presentation transcript:

Volume 26, Issue 2, Pages 366-378 (February 2018) Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma  Min Yu, Hong Luo, Mingliang Fan, Xiuqi Wu, Bizhi Shi, Shengmeng Di, Ying Liu, Zeyan Pan, Hua Jiang, Zonghai Li  Molecular Therapy  Volume 26, Issue 2, Pages 366-378 (February 2018) DOI: 10.1016/j.ymthe.2017.12.012 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Generation of NK-92/9.28.z Cells Harboring the Second Generation of GPC3-Specific CAR by Lentiviral Vector Transduction (A) Schematic representation of GPC3-specific CAR and the lentiviral vector. The construct consisted of a CD8α signal peptide (SP), a humanized GPC3-specific single-chain variable fragment (scFv) (hu9F2), a CD8α signal hinge region, and CD28 transmembrane region (TM), followed by the intracellular domains of co-stimulatory CD28 and the intracellular domain of CD3ζ. (B) Flow cytometric analysis of CAR expression on the surface of parental NK-92, mock, and NK-92/9.28.z cells with goat anti-human biotin-conjugated anti-Fab antibody followed by PE-conjugated streptomycin. Gating was based on the same cells stained with isotype-matched antibody. Data shown are representatives of experiments with similar results. (C) Western blotting analysis of CAR expression in parental NK-92 and NK-92/9.28.z cells. A CD3ζ-specific antibody was used to detect endogenous and chimeric CD3ζ. Data shown are representatives of at least three experiments with similar results. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 2 Enhanced Cytotoxicities of NK-92/9.28.z Cells against GPC3+, but Not GPC3−, HCC Cell Lines (A) Cytotoxic activity of NK-92/9.28.z, mock, or parental NK-92 cells against GPC3+ (including GPC3+ variants SK-HEP-1/GPC3 and SMMC-7721/GPC3) and negative targets. The effector cells were co-cultured for 6 hr with target cells (1 × 104) at an E:T ratio of 3:1, 1:5:1, and 0.75:1 in a total volume of 100 μL. (B) Cytotoxicity of NK-92/9.28.z, mock, or parental NK-92 cells against Huh-7 at a low E:T ratio while extending the co-culture time to 18 hr. (C) Cytotoxicity of NK-92/9.28.z cells or parental NK-92 cells against Huh-7 under normoxia (20%) or hypoxia (1%). (D) Cytotoxicity of NK-92/9.28.z cells or their counterpart CAR-T cells against Huh-7 in the presence of 5 to 20 ng/mL of human TGF-β1 at an E:T ratio of 3:1 for 24 hr. (E) cytotoxicity of NK-92/9.28.z cells against Huh-7 in the presence of mammalian cell-expressed, soluble GPC3N, GPC3ΔGPI, and BSA at an E:T ratio of 3:1 for 6 hr. NS, not significant. Cytotoxicity was determined by LDH release assays. Data reflect the mean ± SEM of three separate experiments. *p < 0.05, **p < 0.01, and ***p < 0.001, compared with parental NK-92 cells at the same E:T ratios or concentrations. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 3 Phenotypic Characterization and IFN-γ Production of NK-92/9.28.z Cells (A) Flow cytometric analyses of phenotypic characterization of NK-92/9.28.z cells. NK-92/9.28.z or parental NK-92 cells were either cultured with or without Huh-7 or K562 cells for 6 hr, and surface expression of NKp30, NKp44, Nkp46, NKG2D, and CD107a was assessed using mean fluorescence intensity (MFI). Gating was based on the same cells stained with isotype-matched antibody. Data presented are the quantitative data. (B) Representative flow cytometric dot plots illustrating CD107a expression on NK-92/9.28.z or parental NK-92 cells after 6 hr of co-culture with medium, Huh-7, SK-HEP-1, SK-HEP-1/GPC3, and phorbol-12-myristate-13-acetate or ionomycin (PMA/IONO). The same cells stained with isotype-matched controls were used for gating. (C) Depicted data for histograms shown in (B). (D) IFN-γ production by NK-92/9.28.z, mock, or parental NK-92 cells when co-cultured with the indicated HCC cell lines at an E:T ratio of 1.5:1 for 24 hr. (E) Correlation between the IFN-γ production from NK-92/9.28.z cells and the MFI of GPC3 expression on the HCC cell lines. Data presented are the mean ± SD of three separate experiments. *p < 0.05, **p < 0.01, and ***p < 0.001, compared with parental NK-92 cells. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 4 Target-Dependent Growth-Suppressive Effects of NK-92/9.28.z Cells on GPC3-Transfected SK-HEP-1 Tumor Xenografts (A) Growth curves of SK-HEP-1/GPC3 and SK-HEP-1 xenografts treated with NK-92/9.28.z or parental NK-92 cells or PBS (n = 6). Red arrows, days on which the cyclophosphamide pretreatments were delivered; black arrows, days on which the indicated treatments were administered; treatment was repeated every 5–6 days for 4 weeks. (B) Tumor weight of the individual mice from each treatment group the day the experiment was terminated. (C) Accumulation of NK-92/9.28.z cells in SK-HEP-1/GPC3 xenografts. NK-92/9.28.z or parental NK-92 cells were labeled with CFSE and intravenously injected into mice bearing SK-HEP-1/GPC3. After 36 hr, tumors were excised and analyzed for the presence of CFSE-labeled cells. Representative flow cytometric data from one animal of each group are shown (n = 3). (D) Representative tumor sections stained with CD56, Ki67, and cleaved caspase-3 are shown. The specimens were harvested from SK-HEP-1/GPC3 xenografts sacrificed after the study was terminated. Nuclei are stained with hematoxylin. Magnification, 200×. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001, compared with mice treated with parental NK-92 cells. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 5 Therapeutic Effectiveness of NK-92/9.28.z Cells against HCC Xenografts with High or Low Endogenous GPC3 Expression (A) Growth curve of Huh-7 subcutaneous xenografts treated with the indicated NK-92 cells or PBS (n = 6). Treatment was repeated every 4 days. (B) Body weights of the individual mice from each treatment group at the endpoint. (C) Growth curve of PLC/PRF/5 xenografts treated with the indicated NK-92 cells or PBS (n = 6). Treatment was repeated every 4–5 days for 4 weeks. (D) Tumor weights of the individual mice from each treatment group at the endpoint. (E) NK-92/9.28.z cells were irradiated with 10 Gy, and viabilities were determined by counting viable cells at different time points using trypan blue exclusion. (F) Tumor-killing activities of irradiated or non-irradiated NK-92/9.28.z cells against PLC/PRF/5 cells varied with time at an E:T ratio of 3:1. (A–D) Red arrows, days on which the cyclophosphamide pretreatments were administered; black arrows, days on which the indicated treatments were delivered. Data are presented as the mean ± SD. NS, not significant. ***p < 0.001, compared with mice treated with parental NK-92 cells. (E and F) Data reflect the mean ± SEM of three triplicates. ***p < 0.001, compared with non-irradiated NK-92/9.28.z cells at the same time or E:T ratios. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 6 Efficient Redirecting of GPC3-Specific CAR in Primary Human NK Cells (A) Representative flow cytometry dot plots illustrate expression of GPC3-specific CAR in untransduced and transduced NK cells. (B) Intracellular IFN-γ in response to SK-HEP-1 and SK-HEP-1/GPC3 was detected with anti-human IFN-γ-PE antibody by flow cytometry. The same cells stained with isotype-matched controls were used for gating. Data shown are representatives of experiments with similar results. (C) Cytotoxicity of untransduced and CAR-expressing NK cells against Huh-7 and HepG2 cells determined by LDH release assays. (D) Cytotoxicity of untransduced and CAR-expressing NK cells against non-transformed PBMCs determined by LDH release assay. Data reflect the mean ± SEM of three triplicates. ***p < 0.001, compared with untransduced NK cells at the same E:T ratios. Molecular Therapy 2018 26, 366-378DOI: (10.1016/j.ymthe.2017.12.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions